Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

2710 Reed Road, Suite 160, Houston, United States

bambus3001 Feb. 23 at 7:38 PM

$PSTV Geduld, Geduld, Geduld Wir haben gerade Politische Unsicherheiten mit dem Iran Und den Zöllen usw,doch es werden die guten Daten die Kurse bei PSTV schon anschieben .

0 · Reply

Love_To_Learn Feb. 23 at 7:10 PM

$PSTV CHANGING UPDATE ALL U[UPDATE PORTALS NOW

0 · Reply

DIDI_MAGIC Feb. 23 at 6:46 PM

$PSTV can you see the $0,30+ without news???

0 · Reply

Love_To_Learn Feb. 23 at 4:29 PM

$PSTV EXECUTING SEPT 2023 IN MARKET WITH NCI KIDS AND A WHOLE LOT GOING ON ! WILL NEED TO USE PRE RS SEVERAL YEARS AGO TOPS * FROM 0.28* THEIR 0.31 POP FROM LOWER AND THEN DIP AND THEN THEIR RS SEGMENTING THIS POTION OF IT AS WE GET BACK BIOC IN OUR VAULT

0 · Reply

Love_To_Learn Feb. 23 at 4:28 PM

$PSTV SWAPPING BACK IN BIOC AND LPTX REMOVING LPTX SHARES BRINGING BACK BIOC FROM PALI

0 · Reply

Love_To_Learn Feb. 23 at 4:27 PM

$PSTV ACCESSING BIOC FROM THE VAULT

0 · Reply

Love_To_Learn Feb. 23 at 4:18 PM

$PSTV FINISHED CHANGING THE 0.26* IT IS THE KEY NOW * 4 THIS SET UP AND WINDOW

0 · Reply

Love_To_Learn Feb. 23 at 4:15 PM

$PSTV USED UOKA ON THE 0.1861 AND 0.2026 ETC MESSAGES EARLIER FOR NOW AS WE ROTATE FAKEOUTS TO PANDORA AS SHE COMES IT RISKS OUR 0.07* BUT IT MUST B DONE *

0 · Reply

Love_To_Learn Feb. 23 at 4:15 PM

$PSTV PANDORA IS GETTING A BIT MORE AGGRESSIVE EVER SO SLIGHTLY BUT THAT IS STILL A LOT WHY USING ALL TRACE PATTERNS ETC U NOTICE ALOT OF MOVERS USING THE 0.62/0.66 0.72 0.77 ETC 1.03 ANOMALY ETC

0 · Reply

Love_To_Learn Feb. 23 at 4:14 PM

$PSTV WILL HAVE TO CHANGE HOW OUR 0.26 IS PLACED DUE TO TURNING ON OUR 0.07* 026* CHANGING IT NOW KEY WINDOW TO DO THIS SO TAKE NOTE OF THE 0.26*

0 · Reply

Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript

Jan 21, 2026, 4:15 PM EST - 4 weeks ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 11:36 AM EST - 5 weeks ago

Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Jan 14, 2026, 8:00 AM EST - 5 weeks ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 8, 2026, 7:30 AM EST - 6 weeks ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 2 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 2 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 2 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 4 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 8 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 8, 2025, 7:00 AM EDT - 10 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 15, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Mar 27, 2025, 7:42 PM EDT - 11 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 11 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 19, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 11, 2025, 11:00 AM EDT - 1 year ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 7, 2025, 7:30 AM EST - 1 year ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025, 7:30 AM EST - 1 year ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 5, 2025, 4:01 PM EST - 1 year ago

Plus Therapeutics Announces New Employment Inducement Grants

Mar 4, 2025, 2:06 PM EST - 1 year ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

bambus3001 Feb. 23 at 7:38 PM

$PSTV Geduld, Geduld, Geduld Wir haben gerade Politische Unsicherheiten mit dem Iran Und den Zöllen usw,doch es werden die guten Daten die Kurse bei PSTV schon anschieben .

0 · Reply

Love_To_Learn Feb. 23 at 7:10 PM

$PSTV CHANGING UPDATE ALL U[UPDATE PORTALS NOW

0 · Reply

DIDI_MAGIC Feb. 23 at 6:46 PM

$PSTV can you see the $0,30+ without news???

0 · Reply

Love_To_Learn Feb. 23 at 4:29 PM

0 · Reply

Love_To_Learn Feb. 23 at 4:28 PM

$PSTV SWAPPING BACK IN BIOC AND LPTX REMOVING LPTX SHARES BRINGING BACK BIOC FROM PALI

0 · Reply

Love_To_Learn Feb. 23 at 4:27 PM

$PSTV ACCESSING BIOC FROM THE VAULT

0 · Reply

Love_To_Learn Feb. 23 at 4:18 PM

$PSTV FINISHED CHANGING THE 0.26* IT IS THE KEY NOW * 4 THIS SET UP AND WINDOW

0 · Reply

Love_To_Learn Feb. 23 at 4:15 PM

$PSTV USED UOKA ON THE 0.1861 AND 0.2026 ETC MESSAGES EARLIER FOR NOW AS WE ROTATE FAKEOUTS TO PANDORA AS SHE COMES IT RISKS OUR 0.07* BUT IT MUST B DONE *

0 · Reply

Love_To_Learn Feb. 23 at 4:15 PM

$PSTV PANDORA IS GETTING A BIT MORE AGGRESSIVE EVER SO SLIGHTLY BUT THAT IS STILL A LOT WHY USING ALL TRACE PATTERNS ETC U NOTICE ALOT OF MOVERS USING THE 0.62/0.66 0.72 0.77 ETC 1.03 ANOMALY ETC

0 · Reply

Love_To_Learn Feb. 23 at 4:14 PM

$PSTV WILL HAVE TO CHANGE HOW OUR 0.26 IS PLACED DUE TO TURNING ON OUR 0.07* 026* CHANGING IT NOW KEY WINDOW TO DO THIS SO TAKE NOTE OF THE 0.26*

0 · Reply

marketorder Feb. 23 at 4:07 PM

$PSTV market ugly PSTV pretty looking like a breakout to the upside

0 · Reply

Love_To_Learn Feb. 23 at 3:56 PM

$PSTV NEED TO TWEAK OUR 0.07'S @ LOWER RANGE

0 · Reply

Love_To_Learn Feb. 23 at 1:55 PM

$PSTV 0.26 AND CHANGE AND 0.28 AND CHANGE YEARS AGO OLD BIG BOY PIVOT ZONE REPRESENT ENTIRE MARKET AS A WHOLE THESE ZONES BEGINNING THE TRANSITION AND CONVERTING OF VOLUME AND SHARE TYPES VOLUME TYPES USING US ! OLD FOLLOWERS WILL KNOW ALL OF THIS LET US PROCEED *

0 · Reply

Love_To_Learn Feb. 23 at 1:54 PM

$SGN $GOSS 0.62/0.66 OLD VISL TRACE PATTERNS AND $GOSS 0.72/0.77 OLD TBLT FULL FRAG SET UP ENGAGING DETONATION SEQUENCE TO SEPARATE FROM NANO PARTICLE TEMP $PSTV AND THE 1.03 ANOMALY AND 1.17 ANOMALY 4.42 ANOMALY 3.24 ANOMALY ALL ONLINE ACTIVATING ALL THEIR SPECIAL ABILITIES SIMULTANEOUSLY 4 THE 1ST TIME EVER ACROSS THE ENTIRE MARKET

0 · Reply

Love_To_Learn Feb. 23 at 1:36 PM

$PSTV PREPARING A 19.010 MILL CANDLE SOONISH LATER

0 · Reply

Love_To_Learn Feb. 23 at 1:30 PM

$TIRX CONVERTING OLD *$HCTI WHICH R REALLY BELOVED DILUTION FROM B4 $PSTV

0 · Reply

Love_To_Learn Feb. 23 at 1:07 PM

$UHG ME ALL OF THE UNHALT CODING BELOVED $PSTV

0 · Reply

Love_To_Learn Feb. 23 at 1:06 PM

$NCI NOW USING OLD ABIO DR FUSING THEIR DIP WITH $SLS SHORTLY AFTER THEIR RS AND BELOVED * POST RS AND RS CIRCUMSTANCE AND DELISTING CIRCUMSTANCE ADDRESSING THESE MATTERS * $PSTV

1 · Reply

Love_To_Learn Feb. 23 at 1:01 PM

$PSTV TURNING ON OUR 1.55 POCKET IN ADVANCE IT WILL CREATE MOVEMENT ON ALL STOCKS AROUND THAT RANGE AS THEY USE IT SO TAKE NOTE *

0 · Reply

Love_To_Learn Feb. 23 at 12:29 PM

$PSTV THESE EVENTS ALLOW US TO TEMP SEPARATE FROM NANO PARTICLE B4 PANDORA ENGULFS US AND NANO PARTICLE WILL MOVE ON HER OWN CHANNEL AND PLANE THROUGH THE MARKETS USING NUMEROUS TOOLS @ HER DISPOSAL MANY SOME 1 BEING THE NUMEROUS RANGES IVE PLANTED AND BUILT MR HEDRICKS SHARES THROUGH THE MARKET RANGE

0 · Reply

Love_To_Learn Feb. 23 at 12:24 PM

$PSTV ABP* THEY TOOK 1 FO MANY SCENARIOS OF OUR FATE LIKE THE HUNDREDS WHO HAVE ALREADY &

0 · Reply

Love_To_Learn Feb. 23 at 12:19 PM

$PSTV PEGGING NANO PARTICLE TO EVENTS AND *TIMING OF ISRAEL NO OTHER CONNECTION TO IT THAN TIMING COMING SOON.* WILL TURN ON OUR 0.20.26 AND 0.1861 FILLER FOR OUR LOWER RANGE. AS THE 0.29-0.31 RES SHOWING ROTATES OFF THE BACK N FORTH *

1 · Reply

Market Cap	38.20M
Revenue (ttm)	5.82M
Net Income (ttm)	-12.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.02%
Debt to Equity Ratio	0.00

Volume	2,854,265
Avg Vol	10,587,836
Day's Range	N/A - N/A
Shares Out	138.90M
Stochastic %K	62%
Beta	0.89
Analysts	Strong Sell
Price Target	$6.38